Breaking Research News from sources other than Breastcancer.org

BSandra · September 2021

Posted this in clinical trial thread but want to repost it here too:

Dear all, it is so cool Covid-19 helped to advance mRNA technology that is coming into cancer world. What a great idea to make your body produce leukocytes with vaccine-induced cancer antigens. I think it will become another great tool in combination with existing drugs: https://www.fiercebiotech.com/research/biontech-re.... There's also a recruiting clinical trial there for solid tumors. In my list! Hooray!

Saulius

GoKale4320 · September 2021

https://www.mdanderson.org/cancerwise/what-is-tumo...

This article is about TILs therapy. Judy Perkins benefited from this therapy but she also had a gene mutation. I don't know if a patient has to have a gene mutation for this to work. It also says that TILs works on solid tumors. Do you think that includes bone mets? I will ask my MO about this later this month.

BevJen · September 2021

GoKale,

I'd be interested in hearing what your doc says. To my knowledge, this is still being tested. However, I had had the NIH trials bookmarked and recently pulled up that bookmark and it looks like they are not currently taking patients. I don't know if this is related to the actual testing or related to Covid stuff -- because the TIL therapy requires, to my knowledge, going in and out of the hospital for different periods of time.

Anonymous · September 2021

https://youtu.be/yibGZnO0n0s

Interesting video- SBRT is becoming more of an option! But has a way to go.

Dee

2019whatayear · September 2021

Did anyone see this - very relevant to Stage4 ER pos —https://www.sciencedirect.com/science/article/pii/S2059702921001927

BevJen · September 2021

Whatayear,

Very interesting article. When I started on palbo, I read through all of the paperwork and raised with the NP assigned to my oncologist that I was taking a PPI. She passed it off and just said -- don't take them at the same time. Make sure you have a 2 hour window between the two drugs. I got about a year and a half on palbo -- sounds like her advice may not have been exactly on point.

KBL · September 2021

Wow, great article. I also sporadically took a PPI, maybe three or four times in the two years on Ibrance. I am switching to Xeloda. She did tell me that Pantoprazole could interfere so try Tums or something else. Pantoprazole never made any difference to me. It didn’t really help. Thank you for sharing.

GoKale4320 · September 2021

Whatayear - that is an interesting article. I had to look up PPI to see what it was. I also read that people taking a PPI for a year or longer (not cancer patients) have an increased risk of breaking a hip. Yikes! I don't take PPI, and had to confirm that Rolaids are not a PPI. This is great information to know because a nurse had casually mentioned Protonix, and that I should discuss it with the MO. I just looked it up and it is a PPI. So I am glad to know this information, Whatayear. Thanks!

Tinkerbell107 · October 2021

In an interview with Targeted Oncology for Metastatic Breast Cancer Awareness Day, O'Regan discussed how the metastatic breast cancer landscape has changed and suggested potential regimens that could further that change.

https://www.targetedonc.com/view/o-regan-highlight...

LillyIsHere · October 2021

Tinkerbell, very interesting.

Have you seen Lumpie?

GoKale4320 · October 2021

Tinkerbell - thank you for posting that article. It was quite honest, but also hopeful. No mention of the ErSO med, though.

moth · October 2021

interstitial lung disease is a problem with ADCs used for her2+ tx

Pls share with her2+ peeps so they're aware & vigilant to report symptoms such as shortness of breath.

https://jamanetwork.com/journals/jamaoncology/arti...

Twitter thread by lead author https://twitter.com/PTarantinoMD/status/1448679136...

Tinkerbell107 · October 2021

LillyisHere: I hope Lumpie is taking a break from these boards. I looked forward to her sharing the latest research information. Until she returns I hope anyone sees anything research worthy please post. Thanks

elenas401 · October 2021

I've been reading more about Erso too. Sounds very hopeful except for how slowly things move to trial. I hope we can all keep the conversation going on this and possibly bombard the researchers with questions about it to hopefully get things moving. It really sounds like this could be different than these meds that just string us along for a few more months. Wouldnt it be great if these drugs that just extend life by a few more months than the last one could be put out of business by something that finally looks like more of a cure for this type of breast cancer.

GoKale4320 · October 2021

Elenas401 - Yes, I completely agree about ErSO. I am going to ask my husband to hunt down several people and their email addresses to try to get some answers about clinical trials. He's retired and I am not so he has more time to hunt for information; though I am positive, I am more motivated! haha!

Anonymous · October 2021

cross posting from clinical trials thread

https://www.annalsofoncology.org/article/S0923-7534(21)04498-7/fulltext#fig1

Not sure if I agree with everything the article says, but, this very detailed ESMO article gives recommendations for lines of therapy

In ER+ notice that targeted therapies are preferred to chemo for the first 2 lines in most cases. This should help more patients who don't respond and are interested in clinical trials be eligible due to the rigid restrictions of lines of chemo.

ER positive Second-line treatment after CDK 4/6 +ET

o Selection of second-line therapy (ChT versus further ET-based therapy) should be based on disease aggressiveness, extent and organ function, and consider the associated toxicity profile.
o Alpelisib/fulvestrant is a treatment option for patients with PIK3CA-mutant tumours (in exons 7, 9 or 20), prior exposure to an AI (± CDK4/6 inhibitors) and appropriate HbA1c levels [I, B; ESMO-MCBS v1.1 score: 2; ESCAT score: I-A].
o Everolimus/exemestane is an option since it significantly prolongs PFS [I, B; ESMO-MCBS v1.1 score: 2]. Tamoxifen or fulvestrant can also be combined with everolimus [II, B]. If everolimus is used, stomatitis prophylaxis must be used.
o PARP inhibitor monotherapy (olaparib or talazoparib) should be considered for patients with germline pathogenic BRCA1/2 mutations [I, A; ESMO-MCBS v1.1 score: 4; ESCAT score: I-A] and as an option for those with somatic pathogenic or likely pathogenic BRCA1/2 or germline PALB2 mutations.
o At least two lines of endocrine-based therapy are preferred before moving to ChT
Dee

Cure-ious · October 2021

Apparently there is still a dearth of great mouse models that support extensive breast cancer metastasis. Scientists have now created a better model by engineering mice to express the human version of the hormone prolactin, and it supports more extensive metastases- in addition, they showed two different prolactin blocking drugs inhibited lung mets in the new mouse model,

https://www.sciencedaily.com/releases/2021/10/2110...

HomeMom · October 2021

Cure-ious Reading that was very enlightening, thank you for sharing. It's interesting that I had a tough time producing milk when I tried to breastfeed any of my three children, yet I ended up with ER+ (97%) BC. I also took birth control pills from 19 to 33 y/o, but it was 21 years later that I was diagnosed.

The other takeaway I had was that I keep seeing each type of BC, take turns as the deadliest. Seven years ago I was diagnosed and told I had "good guy" cancer (oxymoron) because I can take a pill after treatment. Triple negative? We throw chemo at it and see if it works. HER+? Very aggressive, they will try to save your life! Fast forward to today --- Now the women who most die from BC are ER+?

The fact they now have this and at least one possible treatment if it spreads to the lungs, is exciting.

elenas401 · October 2021

Curious: Thanks for a sharing that info. I'm wondering why though we just don't hear more everyday about the research into Erso which seems to be the most promising thing on the Horizon for MBC. Whatever it takes to move it along quickly would be good, like the demand grew for HIV drugs years ago.

GoKale4320 · October 2021

I keep googling ErSO to see if there is any news, and I find only articles from July 2021. Here is Bayer's website https://www.bayer.com/en/contact-us I used their "contact us" form to send them an email just now asking about clinical trials.

This page on the Bayer site https://www.bayer.com/en/pharma/access-investigati... show information on how to try a new drug that hasn't gotten FDA approval yet.

GoKale4320 · October 2021

https://clinicaltrials.gov/ct2/show/NCT04708860 This trial is looking at the effects on progression in MBC patients with Hr+ breast cancer when they do nightly prolonged fasting (greater than 13 hours) and moderate exercise 120 minutes per week with 2 weight lifting sessions per week for 12 weeks. Study participants taking either Ibrance or Piqray along with endocrine therapy. Study concludes 9/30/2021 with results July 2022. I will be curious to see the results. I have been doing prolonged nightly fasting most days since 2017 plus more exercise than this study suggests (and it didn't prevent metastasis). Even though it didn't work for me, it's easy to do so I will keep at it.